[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100588278":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":30,"locations":41,"responsibleParty":68,"collaborators":70,"id":73,"slug":74,"hasResults":75,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":75,"sex":81,"minAge":82,"maxAge":18,"enrollmentInfo":83,"targetDuration":18,"studyType":86,"phases":87,"briefSummary":89,"conditions":90,"keywords":94,"overallStatus":43,"whyStopped":18,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":110},{"fullName":5,"class":6},"University Hospital, Angers","OTHER_GOV",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Use of the software Log-AFTER","EXPERIMENTAL","Patients are monitored with the help of LOG-AFTER software. Patients are advised to report the completion of the examinations (date and overall conclusion), which allows the software to function properly. The GP is also advised to report any consultations his patient has had with him and to update the date of the examinations if his patient has not done so.",[13],"Other: Use of the Log-AFTER software",{"label":15,"type":16,"description":17,"interventionNames":18},"WITHOUT Log-After","NO_INTERVENTION","Patients are monitored without the LOG-AFTER software.",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":18},"OTHER","Use of the Log-AFTER software","The LOG-AFTER software is used for long-term follow-up care after cancer to empower patients",[9],[26],{"name":27,"affiliation":28,"role":29},"Charlotte DEMOOR-GOLDSCHMIDT, Dr","University Hospital of Angers","PRINCIPAL_INVESTIGATOR",[31,37],{"name":32,"role":33,"phone":34,"phoneExt":35,"email":36},"Sandra MERZEAU","CONTACT","(+33)2 41 35 59 70","+33","samerzeau@chu-angers.fr",{"name":38,"role":33,"phone":39,"phoneExt":35,"email":40},"Pascal VEILLON","(+33)2 41 35 49 59","paveillon@chu-angers.fr",[42],{"facility":28,"status":43,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"RECRUITING","Angers","Maine Et Loire","49933","France","FR",{"type":50,"coordinates":51},"Point",[52,53],-0.55202,47.47156,{"lat":53,"lon":52},[56,59,61,62,64,66],{"name":27,"role":33,"phone":57,"phoneExt":35,"email":58},"(+33)2 41 35 38 63","Charlotte.DemoorGoldschmidt@chu-angers.fr",{"name":60,"role":33,"phone":39,"phoneExt":35,"email":40},"Pascal VEILLON, project manager",{"name":27,"role":29,"phone":18,"phoneExt":18,"email":18},{"name":63,"role":29,"phone":18,"phoneExt":18,"email":18},"Natacha ENTZ-WERLE, Pr",{"name":65,"role":29,"phone":18,"phoneExt":18,"email":18},"Amandine BERTRAND, Dr",{"name":67,"role":29,"phone":18,"phoneExt":18,"email":18},"Eric THEBAULT, Dr",{"type":69,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR",[71],{"name":72,"class":6},"National Cancer Institute, France","100588278","log-i---impact-study-of-log-after-software-on-long-term-monitoring-of-former-patients-log-i---log-impact-study-100588278",false,"NCT06939322","LOG-I - Impact Study of LOG-AFTER Software on Long-term Monitoring of Former Patients (LOG-I - LOG-Impact Study)","LOG-I - Impact Study of LOG-AFTER Software on Long-term Monitoring of Former Patients (LOG-I - LOG-Impact Study) \u002F Etude d'Impact du Logiciel LOG-AFTER Sur le Suivi à Long Terme Des Anciens Patients (LOG-I - LOG-Impact Study)","LOG-I","Inclusion Criteria:\n\n* Previously treated for cancer or malignant hematological pathology before the age of 25\n* Without residual disease or with a stable disease without treatment for 5 years or more\n* Owning a computer, smartphone or equivalent I-Pad\u002Ftablet with internet access\n* Having signed the consent (or their parents if the patient is a minor, or a third party if necessary)\n* Having 3 or more recommended screenings in their survivorship care plan\n* No access created to LOG-AFTER before the study or having never connected after opening their account if opening an account dating back 24 months or more at the time of inclusion\n\nExclusion Criteria:\n\n* Patient who has relapsed or developed a second cancer with a post-treatment delay \\\u003C 5 years\n* Patient not covered by a health insurance\n* Patient subject to a legal protection measure, patient deprived of liberty by judicial or administrative decision, patient subject to psychiatric care under duress","ALL","15 Years",{"count":84,"type":85},320,"ESTIMATED","INTERVENTIONAL",[88],"NA","Childhood cancer survivors represent a high-risk population that requires risk-based follow-up. Follow-up recommendations have been harmonized. Education and information practices regarding follow-up recommendations should be personalized, to ensure understanding by all survivors, including those with neurocognitive disorders. Individualized follow-up is necessary to detect complications that may increase morbidity and decrease quality of life, or even increase the risk of early mortality.\n\nIn France, the LOG-AFTER software was developed in 2017 by university hospital of Angers and Epiconcept (approved health data host). The main differences with the European procedure concern radiotherapy information, the link with the General practitioner (GP), and the possible addition of information and\u002For access to therapeutic education in a video format. Indeed, there is the possibility of creating an GP account allowing to receive notifications concerning the follow-up of his patient to be scheduled, to have access to his file summary and his personalized follow-up plan, various information and blank prescription models. LOG-I is a study of the impact of the LOG-AFTER software for the \"patient\u002FGP\" couple on adherence to follow-up recommendations. LOG-I is interested in all former patients with at least 3 recommendations in their personalized follow-up plan, taking into account the specific population of patients cured of a brain tumor.",[91,92,93],"Pediatric Cancer","Cancer Survivor","Hemato-oncologic Patients",[95,96,97,98,99,100],"pediatry","oncology","hematology","radiotherapy","survivorship","preventive care","2025-06-27",{"date":103,"type":104},"2025-07-02","ACTUAL",{"date":106,"type":104},"2025-06-06",{"date":108,"type":85},"2030-06-06",{"name":5,"class":6},1]